selegiline
selegiline structure
|
Common Name | selegiline | ||
|---|---|---|---|---|
| CAS Number | 14611-51-9 | Molecular Weight | 187.28100 | |
| Density | 0.954g/cm3 | Boiling Point | 272.5ºC at 760 mmHg | |
| Molecular Formula | C13H17N | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 108.4ºC | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
Use of selegilineSelegiline is a selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. |
| Name | (-)-selegiline |
|---|---|
| Synonym | More Synonyms |
| Density | 0.954g/cm3 |
|---|---|
| Boiling Point | 272.5ºC at 760 mmHg |
| Molecular Formula | C13H17N |
| Molecular Weight | 187.28100 |
| Flash Point | 108.4ºC |
| Exact Mass | 187.13600 |
| PSA | 3.24000 |
| LogP | 2.18260 |
| Vapour Pressure | 0.00606mmHg at 25°C |
| Index of Refraction | 1.528 |
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Hazard Codes | F,T |
| Risk Phrases | 11-23/24/25-39/23/24/25 |
| Safety Phrases | 7-16-36/37-45 |
| RIDADR | UN 1851 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
| HS Code | 2921499090 |
| HS Code | 2921499090 |
|---|---|
| Summary | 2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
|
Design and application of an in vivo reporter assay for phenylalanine ammonia-lyase.
Appl. Microbiol. Biotechnol. 97(17) , 7877-85, (2013) Phenylalanine ammonia-lyase (PAL) is an important enzyme that links primary metabolism to secondary metabolism. Its efficiency is often a critical factor that affects the overall flux of a related met... |
|
|
A (p)ppGpp-null mutant of Haemophilus ducreyi is partially attenuated in humans due to multiple conflicting phenotypes.
Infect. Immun. 82(8) , 3492-502, (2014) (p)ppGpp responds to nutrient limitation through a global change in gene regulation patterns to increase survival. The stringent response has been implicated in the virulence of several pathogenic bac... |
|
|
Mutational analysis of the (p)ppGpp synthetase activity of the Rel enzyme of Mycobacterium tuberculosis.
Arch. Microbiol. 196(8) , 575-88, (2014) Rel(Mtb), a GTP pyrophosphokinase encoded by the Mycobacterium tuberculosis (Mtb) genome, catalyzes synthesis of (p)ppGpp from ATP and GDP(GTP) and its hydrolysis to GDP(GTP) and pyrophosphate to medi... |
| Eldepryl |
| Jumex |
| (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine |
| N-methyl-N-((R)-1-phenylpropan-2-yl)prop-2-yn-1-amine |
| Selegilina |
| Emsam |
| L-Deprenalin |
| Carbex |
| methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine |
| Selegilinum |
| (S)-(+)-selegiline |
| Selegyline |
| Zelapar |